In addition, liver lipid synthesis markers (FAS) and hepatic fibrosis markers (such as TGF‐ꞵ, α‐SMA, and MMP2) were increased in the WD‐treated group, but these elevations were significantly decreased by the oral administration of both PNVs and EA. The gene discussed is MMP2; the disease is Hepatic fibrosis.